06/11/2014
Federal Register Notice: FDA has determined the regulatory review period for AstraZeneca’s Vandetanib is 4,009 days for exte...06/11/2014
Federal Register Notice: FDA is making available a draft guidance for industry entitled Drug Supply Chain Security Act Implementat...06/11/2014
Federal Register Notice: FDA is making available a guidance entitled Global Unique Device Identification Database (GUDID): Guidanc...06/11/2014
Federal Register Notice: FDA is making available a draft guidance for industry entitled Distributing Scientific and Medical Public...06/10/2014
Federal Register Notice: FDA’s proposed collection of information, “Guidance for Industry and Food and Drug Administra...06/10/2014
Federal Register Notice: FDA is seeking comments on information collection requirements for humanitarian use devices (HUDs). Comme...06/10/2014
Federal Register Notice: FDA has determined the regulatory review period for Mitsubishi Tanabe Pharma Corp.’s Stendra (avana...